BioSpace News Archive

Expanded pivotal Phase 3 REVERSE-IT trial of product candidate bentracimab (PB2452) for reversal of antiplatelet effects of ticagrelor into Canada and dosed first patients outside the United States Resuming enrollment in ongoing Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients with sickle cell disease. Mitapivat is an investigational, oral, small molecule allosteric activator of wil

Dyadic International, Inc., a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced its financial results for the quarter ended September 30, 2020, and recent developments.

- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it is commencing an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. The Company expe

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The filing is available on SEDAR. Financial and corporate highlights include: Completion of financings for gross proceeds of $19.5 million USD through two registered direct offerings. As of September 30, 2020, cash & non-

- Sumitovant Biopharma to acquire all outstanding shares of Urovant it does not already own - Transaction increases Urovant’s ability to provide patient therapies and achieve commercial success as it prepares to launch its first potential therapy, vibegron, for the treatment of patients with overactive bladder (OAB) - Agreement unanimously recommended by Special Committee of Urovant Independent Directors

Urovant Sciences Shareholders to Receive $16.25 per share in cash Urovant Special Independent Committee of the Board Unanimously Recommends that all Shareholders Vote in Favor of the Transaction Agreement Represents Confidence in Urovant’s Future Success Transaction expected to be completed in Q1 2021, subject to approval by a majority of minority shareholders IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urova

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the results of the Phase 3 BOSTON ( Bo rtezomib, S elinexor and Dexame t has on e) study evaluating XPOVIO in patients with relapsed or refractory multiple myeloma were published

Today GattaCo and iAssay announced that they have signed a Memorandum of Understanding (MOU), enabling engineers and scientists to work together to integrate and optimize their products in an effort to provide enhanced rapid serology testing, including COVID-19 antibody testing and electronic test result transmission to federal and state agencies via the cloud at the point of care.

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced its financial and operating results for the three and nine months ended September 30, 2020.